Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 6/20 | 0.56 |
| ▸ | SRC | P12931 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 4/20 | 0.48 |
| ▸ | CES2 | O00748 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | DAO | P14920 | 1/20 | 0.48 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrogen Sulfide SCHEMBL28239188 | 0.98 | CES1 (0.54) | CES1SRCTSHRCES2ALDH1A1 | |
| SCHEMBL11850419 | 0.89 | CES1 (0.47) | CES1SRCTSHRCES2ALDH1A1 | |
| SCHEMBL25930136 | 0.85 | CES1 (0.56) | CES1SRCTSHRCES2ALDH1A1 | |
| SCHEMBL1445897 | 0.83 | CES1 (0.54) | CES1SRCTSHRCES2ALDH1A1 | |
| SCHEMBL4618681 | 0.82 | CES1 (0.58) | CES1SRCTSHRCES2ALDH1A1 | |
| SCHEMBL21109870 | 0.82 | CES1 (0.58) | CES1SRCTSHRCES2ALDH1A1 | |
| SCHEMBL226691 | 0.82 | CES1 (0.58) | CES1SRCTSHRCES2ALDH1A1 | |
| SCHEMBL1553905 | 0.82 | PARP10 (0.56) | ALDH1A1POLBMAPTL3MBTL1 | |
| SCHEMBL1553692 | 0.82 | HPGD (0.61) | CES1ALDH1A1TDP1POLBMAPT | |
| SCHEMBL1799477 | 0.81 | CES1 (0.64) | CES1SRCTSHRCES2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 241 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1721992-B | Star polymer | SUMITOMO CHEMICAL CO | 2011-02-02 | — | — | CN | claimed |
| US-20060258867-A1 | Transition metal complexes, especially iron complexes, used as a catalyst component in the polymerisation of olefins | IC INNOVATIONS LTD. (GB) | 2006-11-16 | — | — | US | claimed |
| CN-1721992-A | Star polymer | SUMITOMO CHEMICAL CO | 2006-01-18 | — | — | CN | claimed |
| WO-2004081020-A1 | TRANSITION METAL COMPLEXES, ESPECIALLY IRON COMPLEXES, USED AS A CATALYST COMPONENT IN THE POLYMERISATION OF OLEFINS | IC INNOVATIONS LTD (GB) | 2004-09-23 | — | — | WO | claimed |
| US-6737486-B2 | USING ORGANIC HALIDE OR SULFUR INITIATOR; MAINTAINING PROCESS CONTROL AND UNIFORMITY | EASTMAN KODAK COMPANY | 2004-05-18 | — | — | US | claimed |
| US-20040014910-A1 | Novel polymerization process | EASTMAN KODAK COMPANY | 2004-01-22 | — | — | US | claimed |
| US-6310165-B1 | VINYL MONOMER WITH ONIUM SALT TRANSITION METAL CAYALYST | EASTMAN KODAK COMPANY | 2001-10-30 | — | — | US | claimed |
| US-6306995-B1 | CATALYTIC POLYMERIZATION WITH ONIUM CATALYSTS | EASTMAN KODAK COMPANY | 2001-10-23 | — | — | US | claimed |
| WO-2001068726-A1 | ATOM TRANSFER RADICAL POLYMERISATION CATALYST | BP CHEMICALS LIMITED (GB) | 2001-09-20 | — | — | WO | claimed |
| US-3982942-A | MANGANESE CARBONYL CATALYST | ICI UNITED STATES INC. (US) | 1976-09-28 | — | — | US | claimed |
| JP-62059267-A | — | — | None | — | — | JP | disclosed |
| US-20250388592-A1 | (AZA)SPIROHEPTANE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | REMYND N.V. (BE) | 2025-12-25 | — | — | US | disclosed |
| EP-4568968-A1 | (AZA)SPIROHEPTANE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Remynd N.V. (BE) | 2025-06-18 | — | — | EP | disclosed |
| US-20250163017-A1 | LANTHIONINE C-LIKE PROTEIN 2 LIGANDS, CELLS PREPARED THEREWITH, AND THERAPIES USING SAME | NIMMUNE BIOPHARMA, INC. (US) | 2025-05-22 | — | — | US | disclosed |
| US-12145920-B2 | Lanthionine c-like protein 2 ligands, cells prepared therewith, and therapies using same | NIMMUNE BIOPHARMA, INC. (US) | 2024-11-19 | — | — | US | disclosed |
| US-4025695-A | LAMINATION | EXXON RESEARCH AND ENGINEERING COMPANY (US) | 1977-05-24 | — | — | US | disclosed |
| US-4010289-A | METHOD OF MANUFACTURING SYNTHETIC RESIN FILM HAVING HIGH WRITABILITY AND PRINTABILITY | SHOWA DENKO KABUSHIKI KAISHA (JA) | 1977-03-01 | — | — | US | disclosed |
| US-3984465-A | DIURETIC, SALURETIC AND URICOSURIC | MERCK & CO., INC. (US) | 1976-10-05 | — | — | US | disclosed |
| US-3982942-A | MANGANESE CARBONYL CATALYST | ICI UNITED STATES INC. (US) | 1976-09-28 | — | — | US | disclosed |
| US-3860429-A | PHOTOPOLYMERIZATION OF ETHYLENICALLY UNSATURATED ORGANIC COMPOUNDS | ICI AMERICA INC | 1975-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163017-A1 | LANTHIONINE C-LIKE PROTEIN 2 LIGANDS, CELLS PREPARED THEREWITH, AND THERAPIES USING SAME | LCP2, LANCL2, SSB | CES1 236/4885SRC 4349/4885TSHR 1609/4885 |
| US-20060258867-A1 | Transition metal complexes, especially iron complexes, used as a catalyst component in the polymerisation of olefins | NR1I3, OPRD1, NR1I2 | CES1 3707/4885SRC 1793/4885TSHR 705/4885 |
| US-12145920-B2 | Lanthionine c-like protein 2 ligands, cells prepared therewith, and therapies using same | LCP2, LANCL2, SSB | CES1 236/4885SRC 4349/4885TSHR 1609/4885 |
| US-20250388592-A1 | (AZA)SPIROHEPTANE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | SNCA, CHRNA6, CHRNA5 | CES1 568/4885SRC 4025/4885TSHR 1240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.